Characteristics of patients with atrial fibrillation prescribed edoxaban in Belgium and The Netherlands: insights from the ETNA-AF-Europe study.

peer reviewed ; BACKGROUND: Studies on the use of non-vitamin K antagonist oral anticoagulants in unselected patients with atrial fibrillation (AF) show that clinical characteristics and dosing practices differ per region, but lack data on edoxaban. METHODS: With data from Edoxaban Treatment in routiNe clinical prActice for patients with AF in Europe (ETNA-AF-Europe), a large prospective observational study, we compared clinical characteristics (including the dose reduction criteria for edoxaban: creatinine clearance 15-50 mL/min, weight ≤60 kg, and/or use of strong p-glycoprotein inhibitors)... Mehr ...

Verfasser: de Vries, Tim A C
Hemels, Martin E W
Cools, Frank
Crijns, Harry J G M
Yperzeele, Laetitia
Vanacker, Peter
Blankoff, Ivan
LANCELLOTTI, Patrizio
Mairesse, Georges H
de Veer, Anne
Casado Arroyo, Ruben
Catez, Emmanuel
de Pauw, Michel
Vanassche, Thomas
de Asmundis, Carlo
Kirchhof, Paulus
De Caterina, Raffaele
de Groot, Joris R
ETNA-AF-Europe principal investigators from Belgium and the
Dokumenttyp: journal article
Erscheinungsdatum: 2021
Schlagwörter: Anticoagulants / Factor Xa Inhibitors / Pyridines / Thiazoles / NDU3J18APO (edoxaban) / Aged / Atrial Fibrillation/complications/drug therapy/epidemiology / Belgium/epidemiology / Europe/epidemiology / Factor Xa Inhibitors/therapeutic use / Humans / Netherlands/epidemiology / Prospective Studies / Pyridines/therapeutic use / Thiazoles/therapeutic use / Treatment Outcome / clinical trial / phase IV / haemorrhage / off-label use / stroke / thromboembolism / Human health sciences / Cardiovascular & respiratory systems / Sciences de la santé humaine / Systèmes cardiovasculaire & respiratoire
Sprache: Englisch
Permalink: https://search.fid-benelux.de/Record/base-27372553
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : https://orbi.uliege.be/handle/2268/290919